Black cohosh Actaea racemosa (Cimicifuga racemosa)
Also called: black snakeroot, macrotys, bugbane, bugwort, rattleroot, rattleweed
Black cohosh, Actaea racemosa (also called Cimicifuga racemosa), is a plant whose root and rhizome (underground stem) are used in supplements. It has been studied mostly for menopause symptoms. It is a different plant from blue cohosh.
- Category
- Botanical
- Part used
- Root and rhizome
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-28
Class 1 Well studied in people. A 2012 Cochrane review identified 16 randomized controlled trials (2,027 peri- or postmenopausal women) of oral black cohosh monopreparations, compared with placebo, hormone therapy, red clover or fluoxetine; its placebo comparisons for hot flushes and symptom scores pooled 3 and 4 trials. [5]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHormones and reproduction3 topics
CCancer1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Menopausal symptoms (Cochrane review) | C | A 2012 Cochrane review of 16 randomized trials (2,027 women) found insufficient evidence to support or oppose black cohosh for menopausal symptoms. [2] |
| Hot flashes and night sweats in large trials | X | A 12-month RCT (351 women) found no difference from placebo at 3, 6 or 12 months; a 2016 meta-analysis (4 studies, 511 women) found no significant reduction in vasomotor symptoms. [2] |
| Overall menopause symptoms (2023 review) | C | A 2023 review of 22 studies, including combination products, found potential benefit for overall menopause symptoms and hot flashes but not for anxiety or depressive symptoms; results conflict with other reviews. [1] |
| Hot flashes from breast cancer treatment | C | NCCIH states it is uncertain whether black cohosh reduces hot flashes caused by breast cancer treatment. [1] |
Main constituents: Triterpene glycosides (actein, 23-epi-26-deoxyactein, cimicifugoside), resins (cimicifugin) and aromatic acid derivatives (caffeic, isoferulic, fukinolic acids); the active compounds are unknown [2]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 2012 Cochrane review: 8–160 mg/day (median 40 mg/day). 2006 RCT: 160 mg/day of a 70% ethanolic extract (2.5% triterpene glycosides). 2009 RCT: 128 mg/day of a 75% ethanolic extract (5.7% triterpene glycosides). [2]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score AABCDEA: well known causeE: unlikely cause
LiverTox likelihood score A: products sold as black cohosh are well established causes of clinically apparent liver injury, but the specific …
Details and sources - Pregnancy and breastfeedingHealth Canada monograph: contraindicated in pregnancy ('Do not use if you are pregnant'); ask a health care practitioner before use if breastfeeding.
3 statements in the profile.
Details and sources - Interactions with medicines3 listed
Estrogens; Medicines in general; Medicines in general
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographs2 statements
EU herbal monograph, well-established use (EMA/HMPC/48745/2017, adopted 27 March 2018), female adults: dry extract (DER 5-10:1, ethanol 58% V/V) 2.8 …
Details and sources
- LiverTox likelihood score A: products sold as black cohosh are well established causes of clinically apparent liver injury, including acute liver failure requiring transplant and death; the component responsible is unclear. Latency 1 to 48 weeks, usually 2 to 12. [3]
- Studies lasting up to a year generally found it well tolerated, but serious liver damage has been reported; NCCIH advises consulting a provider about symptoms such as dark urine and fatigue. [1]
- The USP recommends a label telling people to stop use and consult a practitioner if they have a liver disorder or develop symptoms of liver trouble. Common side effects are mild, transient stomach upset and rashes; long-term safety is unknown. [2]
- It may not be safe during pregnancy or breastfeeding. Safety is uncertain for people with a history of hormone-sensitive conditions such as breast or uterine cancer. [1]
- Blue cohosh (Caulophyllum thalictroides) is a different herb; its use to induce labor has been linked to life-threatening complications in infants. [1]
Interactions
| With | What happens |
|---|---|
| Medicines in general | No clinically relevant medication interactions are known, but interactions have not been systematically studied. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- Many extracts are standardized to at least 1 mg triterpene glycosides per daily dose. [2]
- Some products sold as black cohosh contained Chinese Actaea species (C. dahurica, C. foetida, C. heracleifolia); in several liver-injury cases the retrieved product was Chinese Actaea rather than black cohosh. [3]
- Some commercial products contained the wrong herb or undisclosed mixtures of other herbs; whether these contribute to liver injury has not been proven. [1]
Regulatory status
- US: sold as a dietary supplement ingredient; dietary supplements are not approved by the FDA before sale, and manufacturers are responsible for safety and labeling. [1]
- US: the USP recommended (2008) a liver-related cautionary label; the FDA does not require it. Australia has required a liver warning since 2007. [2]
- EU: the EMA HMPC lists black cohosh (Cimicifugae rhizoma) under well-established use for menopausal complaints such as hot flushes and excessive sweating (EU herbal monograph, revision 1 published 03/07/2018). [4]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Triterpene glycosides (actein, 23-epi-26-deoxyactein, cimicifugoside); ODS states the active compounds are unknown Triterpene glycosides [P2]
- Aromatic acid derivatives (caffeic, isoferulic and fukinolic acids) and resins (cimicifugin) Phenolic acid derivatives; resins [P2]
- Cimiracemoside C (cimigenol-3-O-arabinoside), present in Actaea racemosa but not in most other Actaea/Cimicifuga species Triterpene glycoside (identity marker) [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming black cohosh (Actaea racemosa, syn. Cimicifuga racemosa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P8]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- NTP TR-603 (2023), black cohosh root extract by gavage for 2 years: equivocal evidence of carcinogenic activity in female Hsd:Sprague Dawley SD rats (marginal increases in uterine squamous cell papillomas); no evidence in male rats exposed perinatally; no evidence in female B6C3F1/N mice. Female mice showed disrupted erythropoiesis and more micronucleated erythrocytes at 3 and 12 months. [P6]
- No IARC evaluation of black cohosh (Actaea racemosa) was found (IARC Monographs list of classifications checked 2026-10-29). [P10]
Liver (NIH LiverTox)
- LiverTox likelihood score A: products sold as black cohosh are well established causes of clinically apparent liver injury, but the specific ingredient or component responsible is unclear (chapter last updated April 15, 2025). Cases include acute liver failure requiring transplant and death; latency 1 to 48 weeks, usually 2 to 12. [P3]
Interactions with medicines
- Estrogens: EU monograph: Cimicifugae rhizoma preparations should not be used together with estrogens unless advised by a doctor. [P4]
- Medicines in general: ODS: no clinically relevant medication interactions are known, but interactions have not been systematically studied. [P2]
- Medicines in general: EU monograph: no interactions reported. [P4]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- In a 2006 analysis of 11 black cohosh products, 3 contained the marker cimifugin and not cimiracemoside C, indicating Asian Actaea species instead of black cohosh, and 1 contained both black cohosh and an Asian Actaea species. [P7]
- LiverTox: some black cohosh products are mislabeled and contain Chinese Actaea species (shown by phytochemical analyses); in several liver-injury cases the retrieved product contained Chinese Actaea species. [P3]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P9]
- Validated identity method (HPLC-ELSD, HPLC-MS or HPLC-MS/MS): presence of cimiracemoside C and absence of cimifugin / cimifugin-3-O-glucoside — Health Canada requires unambiguous identification because peer-reviewed cases found products labeled black cohosh to contain other species; other Actaea/Cimicifuga species contain cimifugin derivatives that black cohosh lacks. [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- EU herbal monograph, well-established use (EMA/HMPC/48745/2017, adopted 27 March 2018), female adults: dry extract (DER 5-10:1, ethanol 58% V/V) 2.8 mg twice daily (5.6 mg/day); dry extract (DER 4.5-8.5:1, ethanol 60% V/V) 6.5 mg once daily; dry extract (DER 6-11:1, propan-2-ol 40% V/V) 5.0 mg/day. Not to be taken for more than 6 months without medical advice. [P4]
- Health Canada, Black Cohosh monograph (January 31, 2025), adults 18 and older: 40-2,400 mg dried root and/or rhizome per day. [P5]
Pregnancy and breastfeeding
- Health Canada monograph: contraindicated in pregnancy ('Do not use if you are pregnant'); ask a health care practitioner before use if breastfeeding. [P5]
- EU monograph: safety during pregnancy and lactation has not been established; use is not recommended. Women of childbearing potential should consider effective contraception during treatment. [P4]
- NCCIH: black cohosh may not be safe during pregnancy or breastfeeding. [P1]
Sources for this profile
- NCCIH. Black Cohosh (Last Updated: November 2024), 2024-11. nccih.nih.gov
- NIH Office of Dietary Supplements. Black Cohosh: Fact Sheet for Health Professionals (updated June 3, 2020), 2020-06-03. ods.od.nih.gov
- NIH LiverTox (NIDDK). Black Cohosh (Last Update: April 15, 2025), 2025-04-15. ncbi.nlm.nih.gov
- European Medicines Agency, HMPC. European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizoma, Revision 1 (EMA/HMPC/48745/2017; adopted 27 March 2018), 2018-03-27. ema.europa.eu
- Health Canada, NNHPD. Monograph: Black Cohosh (dated January 31, 2025), 2025-01-31. webprod.hc-sc.gc.ca
- National Toxicology Program. TR-603: Toxicology and Carcinogenesis Studies of Black Cohosh Root Extract (CASRN 84776-26-1) Administered by Gavage to Sprague Dawley (Hsd:Sprague Dawley SD) Rats and Female B6C3F1/N Mice (2023), 2023. ntp.niehs.nih.gov
- Jiang B, Kronenberg F, Nuntanakorn P, Qiu MH, Kennelly EJ. Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by HPLC with selected ion monitoring LC-MS. J Agric Food Chem 2006;54(9):3242-53 (PMID 16637680), 2006-05-03. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
- IARC Monographs. List of Classifications (retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
Sources
- NCCIH. Black Cohosh (Last Updated: November 2024), 2024-11. nccih.nih.gov
- NIH Office of Dietary Supplements. Black Cohosh: Fact Sheet for Health Professionals (updated June 3, 2020), 2020-06-03. ods.od.nih.gov
- NIH LiverTox. Black Cohosh (last update April 15, 2025), 2025-04-15. ncbi.nlm.nih.gov
- European Medicines Agency. Cimicifugae rhizoma (herbal medicine page), 2018-07-03. ema.europa.eu
- Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012;2012(9):CD007244 (PMID 22972105), 2012-09-12. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.